{"id":5017,"date":"2026-04-30T12:30:26","date_gmt":"2026-04-30T02:30:26","guid":{"rendered":"\/eu-uk\/?p=5017"},"modified":"2026-04-30T13:22:42","modified_gmt":"2026-04-30T03:22:42","slug":"orthocell-acheives-first-remplir-sales-in-us75-million-canadian-market","status":"publish","type":"post","link":"\/eu-uk\/blog\/2026\/04\/30\/orthocell-acheives-first-remplir-sales-in-us75-million-canadian-market\/","title":{"rendered":"Orthocell achieves first Remplir\u2122 sales in US$75 million Canadian Market"},"content":{"rendered":"

Orthocell\u00a0has shared\u00a0that\u00a0it has completed the\u00a0<\/span>first commercial sales\u00a0of\u00a0Remplir\u2122 in Canada, marking a key milestone in the Company\u2019s global commercialisation strategy for its\u00a0flagship\u00a0nerve repair medical device.<\/span>\u00a0<\/span><\/p>\n

The first sales\u00a0follow regulatory approval from Health Canada for\u00a0Remplir\u00a0and distributor appointments in 2H CY25, which\u00a0currently\u00a0provide majority national coverage across the Canadian market and position the Company to support surgeon and hospital adoption nationwide.<\/span>\u00a0<\/span><\/p>\n

Orthocell\u00a0has worked alongside its distributors on\u00a0initial\u00a0launch activities, including a KOL-led product roadshow across Canada (Vancouver to Toronto). The program featured Australian orthopaedic surgeon Dr Stuart Kirkham, who presented his clinical experience and use of\u00a0Orthocell\u2019s\u00a0Remplir\u00a0collagen nerve\u00a0repair device to plastic and orthopaedic peripheral nerve surgeons. This activity supported product education and early engagement, contributing to the first commercial\u00a0sales.<\/span>\u00a0<\/span><\/p>\n

Following the Canadian launch,\u00a0Orthocell\u00a0will continue to work closely with its distributor network to onboard surgeons and\u00a0establish\u00a0active accounts, supported by the Company\u2019s existing US-based marketing and medical education teams. This coordinated approach provides clinical engagement, training and operational efficiencies across\u00a0the U.S.\u00a0and Canada.<\/span>\u00a0<\/span><\/p>\n

Orthocell\u00a0Managing Director Paul Anderson said:\u00a0<\/span>\u201cWe are delighted to announce the first commercial sales\u00a0of\u00a0Remplir\u00a0in Canada, a\u00a0key\u00a0milestone following Health Canada approval and\u00a0the roll out of\u00a0our distributor-led model, which provides\u00a0coverage across\u00a0the majority of\u00a0this\u00a0~US$75 million market.\u00a0\u00a0<\/em><\/p>\n

This milestone\u00a0represents\u00a0an important early step in our Canadian\u00a0commercialisation\u00a0strategy and reinforces the strength of our execution. We expect increasing surgeon engagement to support continued adoption and\u00a0further\u00a0revenue growth.\u201d\u00a0<\/em><\/p>\n

Click to read the ASX release<\/span>.<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Orthocell has shared that it has completed the first commercial sales of Remplir\u2122 in Canada, marking a key milestone in the Company\u2019s global commercialisation strategy for its flagship nerve repair medical device. <\/p>\n","protected":false},"author":2,"featured_media":5018,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-5017","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/5017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=5017"}],"version-history":[{"count":2,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/5017\/revisions"}],"predecessor-version":[{"id":5021,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/5017\/revisions\/5021"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/5018"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=5017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=5017"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=5017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}